DK373489A - Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler - Google Patents

Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler Download PDF

Info

Publication number
DK373489A
DK373489A DK373489A DK373489A DK373489A DK 373489 A DK373489 A DK 373489A DK 373489 A DK373489 A DK 373489A DK 373489 A DK373489 A DK 373489A DK 373489 A DK373489 A DK 373489A
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequence
retrovirus
antives
inputing
Prior art date
Application number
DK373489A
Other languages
English (en)
Other versions
DK373489D0 (da
Inventor
Pierre Tiollais
Marie-Louise Michel
Maryline Mancini
Eliane Sobczak
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of DK373489D0 publication Critical patent/DK373489D0/da
Publication of DK373489A publication Critical patent/DK373489A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK373489A 1988-07-29 1989-07-28 Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler DK373489A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8810336A FR2635532B1 (fr) 1988-07-29 1988-07-29 Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant

Publications (2)

Publication Number Publication Date
DK373489D0 DK373489D0 (da) 1989-07-28
DK373489A true DK373489A (da) 1990-01-30

Family

ID=9368968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK373489A DK373489A (da) 1988-07-29 1989-07-28 Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler

Country Status (7)

Country Link
EP (1) EP0354109B1 (da)
JP (1) JPH02211881A (da)
AT (1) ATE136933T1 (da)
DE (1) DE68926274D1 (da)
DK (1) DK373489A (da)
FR (1) FR2635532B1 (da)
PT (1) PT91316B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421626A1 (en) * 1989-09-19 1991-04-10 Merck & Co. Inc. Vaccine for aids and hepatitis B
EP0547689A2 (en) * 1991-12-18 1993-06-23 Merck & Co. Inc. Synthetic peptides comprising a cyclic HIV principal neutralizing determinant and a T-cell stimulatory epitope
WO1993012815A1 (en) * 1991-12-27 1993-07-08 Gensci Limited Method for obtaining recombinant surface antigen of hepatitis b, antigen and vaccine based on it
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
IT1256575B (it) * 1992-12-10 1995-12-11 Cesalpino Andrea Fond Procedimento per la preparazione di immunogeni costituiti da antigeni esogeni capaci di generare non solo la risposta immune dei linfociti t helper,ma anche una efficace risposta dei linfociti t citotossici; e immunogeni cosi' ottenibili.
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
EP1005374B1 (en) * 1997-01-22 2007-04-18 Zycos Inc. Microparticles for delivery of nucleic acid
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0038765B1 (fr) * 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
EP0269520A3 (fr) * 1986-11-21 1988-08-24 Institut Pasteur Rétrovirus du type HIV-2 susceptible de provoquer le sida, et ses constituants antigéniques et nucléiques
WO1988005440A1 (fr) * 1987-01-16 1988-07-28 Institut Pasteur Peptides ayant des proprietes immunologiques 2-hiv-2
AP56A (en) * 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.

Also Published As

Publication number Publication date
ATE136933T1 (de) 1996-05-15
EP0354109B1 (fr) 1996-04-17
FR2635532A1 (fr) 1990-02-23
PT91316A (pt) 1990-02-08
JPH02211881A (ja) 1990-08-23
FR2635532B1 (fr) 1992-05-22
PT91316B (pt) 1995-08-09
DK373489D0 (da) 1989-07-28
DE68926274D1 (de) 1996-05-23
EP0354109A1 (fr) 1990-02-07

Similar Documents

Publication Publication Date Title
DE58906121D1 (de) Rekombinantes Vaccinia-Virus MVA.
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
DK513388D0 (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
DK0725824T3 (da) Immunodominante humane T-celleepitoper af hepatitis C virus
FI935808A (fi) Hepatit-C-virus (HCV) polypeptider
ATE391784T1 (de) Verfahren und reagenzien zur erzeugung einer cd8+t-zellen immunantwort gegen hepatitis b oder c
EP0278940A3 (en) Hepatitis b virus surface antigens and hybrid antigens containing them
DE3852221D1 (de) Tierische Zelle mit darin eingeführtem antigenem Protein.
ATE141946T1 (de) Hiv-2-virusvarianten
DK0588578T3 (da) Immunogener
DK0726758T3 (da) Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
DK373489A (da) Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler
DE69434954D1 (de) Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
CA2057828A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
FI885296A (fi) Rekombinant hiv-2 polypeptid.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
HK1048335A1 (en) Recombinant bifunctional fusion proteins for the clearance of variable viruses
DK204588A (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
ATE128733T1 (de) Monoklonale antikörper gegen hiv gp120.
ATE143373T1 (de) Proteine, vakzine und nucleinsäuren
DK123288D0 (da) Fremgangsmaade til remsning af rekombinant hepatitis b overfladeantigen

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment